A unique D2/D3 antagonist and serotonergic modulator in development for mood disorders

Mood disorders have varying presentations, but a common feature among them is dysfunctional dopaminergic and serotonergic neurotransmission, leading to deficits in emotion and reward processing and cognition.1,2 Restoring balance in dopamine and serotonin neurotransmission may remedy these deficiencies and alleviate a wide range of symptoms.3

Although individual modulation of dopamine or serotonin has shown clinical efficacy in treating mood disorders, there remains a large unmet need to improve symptom control using a multisystem approach.3

ENX-105 has a unique mechanism of action that combines potent D2/D3 receptor antagonism with serotonin modulation and provides an excellent pharmacokinetic profile that supports once-daily dosing.4

Through this unprecedented pharmacology, ENX-105 offers the potential to address a variety of mood disorders. Extensive profiling is underway to prioritize the clinical indications for ENX-105, which may include bipolar disorder, anxious depression, post-traumatic stress disorder, and other stress-related disorders.4

Although mood disorders affect 10% of the US adult population each year,5 there are few effective treatment options ⁠— simultaneously targeting dopamine and serotonin signaling may improve symptom control

+ References and Abbreviations

D2, dopamine receptor 2; D3, dopamine receptor 3.

1. Ressler KJ & Nemeroff CB. Depress Anxiety. 2000;12(Suppl. 1):2–19. 2. Grace AA. Nat Rev Neurosci. 2016;17:524–532. 3. Li X, et al. Neuropsychopharmacology. 2012;37:77–101. 4. Engrail Therapeutics. Data on file. 5. National Institutes of Mental Health. Any Mood Disorder. Accessed June 1, 2022. https://www.nimh.nih.gov/health/statistics/any-mood-disorder.